The benzodiazepines specifically considered by the researchers were the short-acting anti-anxiety medications alprazolam (Xanax), lorazepam (Ativan), oxazepam (Seresta) and diazepam (Valium), and the longer-acting anti-seizure and "hypnotic" drugs frequently used to treat insomnia: clonazepam (Klonopin), flurazepam (Dalmane), midazolam (Versed), nitrazepam (Mogadon), temazepam (Restoril) and triazolam (Halcion).
The authors of the study created an index that gauged the intensity of a participant's benzodiazepine use and found that at the end of a five-year period following an initial prescription, Alzheimer's risk mounted steadily. Those who took the cumulative equivalent of daily doses for three to six months over a five-year period were roughly 32% more likely than those who took none to develop Alzheimer's. Those who took the cumulative equivalent of a full daily dose for more than six months were 84% more likely to do so.
They only gave you half the story though.
Here, this took me one minute to find:
Benzodiazepines induce hyperglycemia in rats by affecting peripheral disposal of glucose
Peripheral-type benzodiazepines inhibit glucose-induced insulin secretion,
These results suggest that a benzodiazepine, in particular clonazepam, may alter insulin secretion and insulin sensitivity after a single administration in healthy volunteers.
Their solution to anxiety: Induce Diabetes. Way to Go Psychs!!!!
